Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.40 |
| ▸ | FYN | P06241 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774424 | 0.89 | POLB (0.46) | BRAFFYNPOLBMEN1KMT2A | |
| SCHEMBL6692603 | 0.84 | BRAF (0.38) | BRAFFYNPOLBMEN1KMT2A | |
| SCHEMBL6696053 | 0.77 | PTGS2 (0.35) | BRAFFYNPOLBMEN1KMT2A | |
| SCHEMBL5774429 | 0.75 | POLB (0.46) | BRAFFYNPOLBMEN1KMT2A | |
| SCHEMBL5776886 | 0.74 | PTGS2 (0.49) | BRAFFYNPOLBMEN1KMT2A | |
| SCHEMBL6691783 | 0.73 | PTGS2 (0.39) | BRAFFYNPOLBMEN1KMT2A | |
| SCHEMBL5774719 | 0.73 | PTGS2 (0.48) | POLBMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5778310 | 0.71 | POLB (0.51) | BRAFPOLBMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL7226348 | 0.71 | PTGS2 (0.45) | BRAFFYNPOLBMEN1KMT2A | |
| SCHEMBL6697312 | 0.71 | FYN (0.38) | BRAFFYNMAPK1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | BONJOUKLIAN ROSANNE (US) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | ABCC1, ABCB1, ABCB11 | BRAF 1466/4885FYN 4849/4885POLB 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.